Invention Grant
US08907096B2 N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase
有权
N-金刚烷基苯甲酰胺作为11-&bgr-羟基类固醇脱氢酶的抑制剂
- Patent Title: N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase
- Patent Title (中): N-金刚烷基苯甲酰胺作为11-&bgr-羟基类固醇脱氢酶的抑制剂
-
Application No.: US14321884Application Date: 2014-07-02
-
Publication No.: US08907096B2Publication Date: 2014-12-09
- Inventor: Soren Ebdrup
- Applicant: High Point Pharmaceuticals, LLC
- Applicant Address: US NC High Point
- Assignee: High Point Pharmaceuticals, LLC
- Current Assignee: High Point Pharmaceuticals, LLC
- Current Assignee Address: US NC High Point
- Agent Samuel B. Rollins
- Main IPC: A61K31/44
- IPC: A61K31/44 ; A61K31/445 ; C07D211/68 ; C07D207/00 ; C07D309/06 ; C07D213/30 ; C07D211/96 ; C07D295/088 ; C07D211/22 ; C07C235/54 ; C07D471/08 ; C07D207/26

Abstract:
Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.
Public/Granted literature
- US20140315905A1 N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE Public/Granted day:2014-10-23
Information query